GlassScriptPhysician profile
Jignesh R Dholaria
NPI 1104019181
$1,220.94
in general payments reported to CMS, 2019-2025
25 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $71.53 · 2021: $91.25 · 2022: $37.78 · 2023: $99.19 · 2024: $124 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $111.74 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Tandem Diabetes Care, INC. | $111.46 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $108.75 | 2019-2025 | Evenity, Prolia |
| Insulet Corporation | $108.72 | 2023-2025 | Omnipod |
| Dexcom, INC. | $78.19 | 2023-2025 | Dexcom G6 Transmitter |
| Welch Allyn | $77.03 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $73.35 | 2019-2024 | Airsupra |
| Sanofi-Aventis U.S. LLC | $68.98 | 2021-2025 | |
| Radius Health, INC. | $62.79 | 2025 | Tymlos |
| Abbott Laboratories | $54.29 | 2022-2025 | Freestyle Libre 3 |
| Almatica Pharma LLC | $38.86 | 2025 | Loreev Xr, Teriparatide |
| Bayer Healthcare Pharmaceuticals INC. | $37.59 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.40 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $33.04 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $30.27 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $24.96 | 2025 | Minimed 780g |
| Sequel Med Tech, LLC | $23.38 | 2025 | Twiist |
| Corium, LLC | $22.86 | 2025 | Azstarys |
| Alexion Pharmaceuticals, INC. | $22.77 | 2025 | Strensiq |
| Novartis Pharmaceuticals Corporation | $20.60 | 2019 | |
| Eisai INC. | $19.34 | 2020 | |
| Amneal Pharmaceuticals LLC | $18.09 | 2025 | Unithroid |
| Merck Sharp & Dohme LLC | $14.52 | 2019 | |
| Glaxosmithkline, LLC. | $13.47 | 2019 | |
| Daiichi Sankyo INC. | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jignesh Dholaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.